custirsen

October 13, 2016October 16, 2016

Metastatic Prostate Cancer Patients Show No Survival Benefit with Custirsen

News

Patients with previously treated metastatic, castration-resistant prostate cancer (mCRPC) see no benefit when custirsen is added to the combination of Jevtana (cabazitaxel) and prednisole, according to the results of a ... Read more

August 24, 2016August 24, 2016

Custirsen Fails to Improve Survival in Advanced Prostate Cancer Patients

News

The Phase 3 AFFINITY trial failed to met its primary endpoint of significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) being treated with custirsen, the therapy’s maker, OncoGenex, announced. The ... Read more

January 6, 2015January 6, 2015

Teva Transfers Prostate Cancer Treatment Resistance Drug Back to OncoGenex

News

OncoGeneX Pharmaceuticals, Inc., a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer, has just announced it has signed an initial agreement contract ... Read more